Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17679765 | 1.00 | HRH3 (0.40) | HRH3CHRM2CHRM1CHRM3BTK | |
| SCHEMBL15938511 | 0.89 | BTK (0.44) | HRH3CHRM2CHRM1CHRM3BTK | |
| SCHEMBL15614036 | 0.89 | BTK (0.44) | HRH3CHRM2CHRM1CHRM3BTK | |
| SCHEMBL29247675 | 0.89 | BTK (0.44) | HRH3CHRM2CHRM1CHRM3BTK | |
| SCHEMBL6436697 | 0.88 | HRH3 (0.45) | HRH3CHRM2CHRM1CHRM3BTK | |
| SCHEMBL583322 | 0.88 | HRH3 (0.45) | HRH3CHRM2CHRM1CHRM3BTK | |
| SCHEMBL15975247 | 0.88 | HRH3 (0.45) | HRH3CHRM2CHRM1CHRM3BTK | |
| Hydrochloric Acid SCHEMBL9469827 | 0.86 | HRH3 (0.44) | HRH3CHRM2CHRM1CHRM3BTK | |
| Hydrochloric Acid SCHEMBL9469820 | 0.86 | HRH3 (0.44) | HRH3CHRM2CHRM1CHRM3BTK | |
| Hydrochloric Acid SCHEMBL29381986 | 0.86 | HRH3 (0.44) | HRH3CHRM2CHRM1CHRM3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218217-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218217-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors | PIK3CA, PIK3CD, PIK3CB | HRH3 1881/4885CHRM2 3743/4885CHRM1 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.